logiover/clinicaltrials-gov-scraper-sample-data huggingface dataset:
Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial
ClinicalTrials.gov ID: NCT00641407
Organization: University of Campania Luigi Vanvitelli
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE4
Conditions: Type 2 Diabetes Mellitus
Hypoglycemia
Interventions: DRUG: NPL insulin
DRUG: Insulin glargine
Lead sponsor: University of Campania Luigi Vanvitelli (OTHER)
Enrollment: 100 participants
Eligibility: sex ALL, minimum age 30 Years, maximum age 70 Years
Accepts healthy volunteers: no
Start date: 2007-01
Completion date: 2008-03
Locations:
facility: Department of Geriatrics and Metabolic Disease
city: Naples
country: Italy

Summary:
The maintenance of nearly normal glycemic levels reduces the risk of diabetic complications, but is difficult to achieve, despite the administration of escalating doses of oral antidiabetic drugs, such as metformin, sulfonylureas, and thiazolidinediones. Most patients eventually require insulin which usually is added when glycemic control with a regimen of oral antidiabetic agents becomes suboptimal.

The aims of the present study were: 1) To compare the clinical efficacy of insulin glargine and neutral protamine lispro (NPL) insulin when added to ongoing oral therapy in poorly controlled type 2 diabetic patients; 2) to find out the possibility to phenotype the patient who may benefit more by the single treatment.

This an open-label, randomized, parallel, 36-week comparative study was performed between January 2007 and March 2008 at a single centre.
A Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 Sublingual Drops for Treating Diabetic Neuropathy
ClinicalTrials.gov ID: NCT04082000
Organization: Breath of Life International Pharma Ltd
Status: TERMINATED
Study type: INTERVENTIONAL
Phases: PHASE1
PHASE2
Conditions: Diabetic Neuropathy
Interventions: DRUG: BOL-DP-o-04
DRUG: Placebo
Lead sponsor: Breath of Life International Pharma Ltd (INDUSTRY)
Enrollment: 2 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 80 Years
Accepts healthy volunteers: no
Start date: 2019-04-15
Completion date: 2020-11-04
Locations:
facility: Wolfson Medical Center
city: Holon
country: Israel

Summary:
This is a randomized, double-blind, placebo-controlled Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 for Treating Diabetic Neuropathy
Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence
Acronym: QCRC-AI
ClinicalTrials.gov ID: NCT07515807
Organization: Weill Cornell Medical College in Qatar
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Conditions: Cardio Vascular Disease
Acute Coronary Syndromes (ACS)
Type 2 Diabetes
Pre Diabetes
Artifical Intelligence
Lead sponsor: Weill Cornell Medical College in Qatar (OTHER)
Collaborators: Hamad Medical Corporation
Enrollment: 10000 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2026-07-16
Completion date: 2030-07-16
Locations:
facility: Hamad Medical Corporation
city: Doha
country: Qatar

Summary:
Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.
An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
ClinicalTrials.gov ID: NCT01847092
Organization: Ardelyx
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE2
Conditions: Chronic Kidney Disease
Type 2 Diabetes Mellitus
Interventions: DRUG: AZD1722
DRUG: Placebo
Lead sponsor: Ardelyx (INDUSTRY)
Collaborators: AstraZeneca
Enrollment: 154 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 80 Years
Accepts healthy volunteers: no
Start date: 2013-05
Completion date: 2015-04
Locations:
facility: Creekside Endocrine Associates PC
city: Denver
state: Colorado
country: United States

Summary:
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer
ClinicalTrials.gov ID: NCT00958711
Organization: Baxter Healthcare Corporation
Status: TERMINATED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Diabetic Foot Ulcers
Interventions: DEVICE: Unite Biomatrix
OTHER: Saline and Gauze
Lead sponsor: Baxter Healthcare Corporation (INDUSTRY)
Collaborators: Synovis Surgical Innovations
Enrollment: 90 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2009-01
Completion date: 2012-05
Locations:
facility: University of California - San Diego
city: San Diego
state: California
country: United States
facility: University of Miami, Miller School of Medicine
city: Miami
state: Florida
country: United States
facility: Aiyan Diabetes Center
city: Evans
state: Georgia
country: United States
facility: Foot & Ankle Associates of Central Illinois, LLC
city: Springfield
state: Illinois
country: United States
facility: Eastern Carolina Foot and Ankle
city: Greenville
state: North Carolina
country: United States
facility: Foot and Ankle East
city: Greenville
state: North Carolina
country: United States
facility: Carolina East Family Medicine
city: Greenville
state: North Carolina
country: United States
facility: Family Foot & Ankle Physicians
city: Greenville
state: North Carolina
country: United States
facility: Comprehensive Wound Care Thoracic & Vascular Associates of Kinston P.A.
city: Kinston
state: North Carolina
country: United States
facility: The Foot & Ankle Associates of North Carolina, PLLC
city: Rocky Mount
state: North Carolina
country: United States
facility: Martin Foot and Ankle
city: York
state: Pennsylvania
country: United States

Summary:
The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and compare its performance with the standard of care, saline moistened gauze, for the treatment of diabetic foot ulcers.
An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy
ClinicalTrials.gov ID: NCT00198471
Organization: Bausch & Lomb Incorporated
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE2
Conditions: Vitreous Detachment
Diabetic Retinopathy
Interventions: DRUG: Vitrase
Lead sponsor: Bausch & Lomb Incorporated (INDUSTRY)
Enrollment: 10 participants
Eligibility: sex ALL, minimum age 50 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2005-07
Completion date: 2006-11
Locations:
facility: Edgar L. Thomas, MD
city: Beverly Hills
state: California
country: United States
facility: Ronni Lieberman, MD
city: New York
state: New York
country: United States
facility: Valley Retina Institute, PA
city: McAllen
state: Texas
country: United States
facility: The Virginia Retina Center
city: Leesburg
state: Virginia
country: United States

Summary:
The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to induce posterior vitreous detachment(PVD) in subjects with moderate to severe non-proliferative diabetic retinopathy.
Effects of Insulin on Hypotension and Sarcopenia
ClinicalTrials.gov ID: NCT03248271
Organization: University of British Columbia
Status: WITHDRAWN
Study type: OBSERVATIONAL
Conditions: Diabetes
Sarcopenia
Hypotension, Orthostatic
Interventions: DRUG: Insulin Lispro
Lead sponsor: Kenneth Madden (OTHER)
Enrollment: 0 participants
Eligibility: sex ALL, minimum age 65 Years, maximum age 
Start date: 2017-10-01
Completion date: 2023-01-10
Locations:
facility: University of British Columbia - Gerontology Research Lab
city: Vancouver
state: British Columbia
country: Canada

Summary:
In this study investigator's aim to determine the impact of insulin therapy on hypotension and sarcopenia
Islet Allotransplantation in Type 1 Diabetes
ClinicalTrials.gov ID: NCT01705899
Organization: Ohio State University
Status: SUSPENDED
Study type: INTERVENTIONAL
Phases: PHASE1
Conditions: Type 1 Diabetes
Interventions: DRUG: Human Pancreatic Islets
Lead sponsor: Ohio State University (OTHER)
Enrollment: 20 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 65 Years
Accepts healthy volunteers: no
Start date: 2006-11
Completion date: 2033-10
Locations:
facility: The Ohio State University Medical Center
city: Columbus
state: Ohio
country: United States

Summary:
Islet transplantation can provide physiologic insulin replacement to patients with type 1 diabetes without the complications associated with whole pancreas transplantation. The purpose of this study is to achieve insulin-independence in patients with type 1 diabetes, thereby eliminating the need for exogenous insulin injections to maintain normal glucose levels, ameliorating severe hypoglycemia and potentially decreasing the development of diabetes-related complications. This study will investigate islet transplantation in subjects who have preserved renal function and subjects who have undergone cadaveric renal transplantation, since the latter subjects are already on immunosuppression.

This is a single center, prospective trial of islet transplantation in subjects receiving islets alone or islets after kidney transplant. This is a phase I study investigating the use of islet transplantation for the treatment of type 1 diabetes. Subjects will be eligible for an islet transplant if they meet all of the inclusion criteria and none of the exclusion criteria outlined in the protocol. In brief, the aims of this study are to establish an islet transplant program at the Ohio State University, determine the safety of islet transplantation in islet alone and kidney transplant recipients, determine whether islet transplantation will reduce the frequency of severe hypoglycemic events, determine whether a novel steroid-free immunosuppressive protocol will prevent rejection in islet transplants and to achieve insulin independence at one year after the final islet transplant.
Application of Information-Motivation-Behavioral Model-based Continuity of Care on the Peri-implantitis Recovery in Diabetic Implant Overdenture Patients: A Randomised Controlled Trial
ClinicalTrials.gov ID: NCT06103799
Organization: The Dental Hospital of Zhejiang University School of Medicine
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Bone Resorption
Diabetes
Interventions: BEHAVIORAL: IMB model-based continuity of care
Lead sponsor: The Dental Hospital of Zhejiang University School of Medicine (OTHER)
Enrollment: 32 participants
Eligibility: sex ALL, minimum age , maximum age 
Accepts healthy volunteers: no
Start date: 2023-01-01
Completion date: 2023-09-30
Locations:
facility: The Stomatologic Hospital, School of Medicine, Zhejiang University
city: Hangzhou
state: Zhejiang
country: China

Summary:
The investigators recruited 32 diabetic IOD patients with a total of 110 problematic implants who had completed the treatment for peri-implantitis between January 2021 and March 2023 as research subjects. The patients were randomly assigned to the control group or the experimental group using the random number table. The control group received routine postoperative medical advice, whereas the experimental group was given an IMB model-based continuity of care.
A Open Label, Parallel Group Phase IIA, Adaptive Design Study of MTX228 in Adult Subjects With Type 1 Diabetes and Preserved β-Cell Function
ClinicalTrials.gov ID: NCT06474598
Organization: University of Alberta
Status: RECRUITING
Study type: INTERVENTIONAL
Phases: PHASE2
Conditions: Type 1 Diabetes Mellitus
Interventions: DRUG: MTX228
DEVICE: DEXCOM G6
Lead sponsor: University of Alberta (OTHER)
Enrollment: 24 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 65 Years
Accepts healthy volunteers: no
Start date: 2024-11-14
Completion date: 2027-12
Locations:
facility: University of Alberta
city: Edmonton
state: Alberta
country: Canada

Summary:
MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing the risk and rate of low blood sugars. This open-label dose selection study aims to determine the optimal dose ofMTX228 for use in a future phase IIb study.

The purpose is to investigate the relative effectiveness of different doses of MTX228 and to select the most effective dose for further investigation in a phase 2b study.
Peau o le Vasa: Accelerating the Currents of Health Advances for Pasifika People
ClinicalTrials.gov ID: NCT07387393
Organization: University of Hawaii
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Phases: NA
Conditions: Cardiometabolic Conditions
Hypertension (HTN)
Dyslipidemia
Pre-diabetes
Type 2 Diabetes Mellitus (T2DM)
Overweight (BMI > 25)
Weight Loss Trial
Interventions: BEHAVIORAL: PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program
Lead sponsor: University of Hawaii (OTHER)
Collaborators: National Association of Pasifika Organizations
Papa Ola Lōkahi
National Heart, Lung, and Blood Institute (NHLBI)
Enrollment: 400 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2026-05-01
Completion date: 2028-10-31
Locations:
facility: National Association of Pasifika Organizations
city: Fayetteville
state: Arkansas
country: United States
facility: Papa Ola Lokahi
city: Honolulu
state: Hawaii
country: United States

Summary:
In this study, the investigators are conducting a Type 3 hybrid effectiveness-implementation trial to evaluate the implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 400 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period.

The aims of this study are threefold:

1. To evaluate the implementation of the PPP across multiple community sites using a Type 3 hybrid effectiveness-implementation design guided by established frameworks such as RE-AIM and PRISM.
2. To examine participant-level outcomes associated with PPP implementation, including changes in cardiometabolic risk factors, health behaviors, and SDOH factors from baseline to 3 and 9-month follow-up.
3. To evaluate the cost and cost-effectiveness of implementing the PPP across community settings.
Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China
ClinicalTrials.gov ID: NCT00408993
Organization: Eli Lilly and Company
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE3
Conditions: Diabetic Neuropathies
Interventions: DRUG: Duloxetine Hydrochloride
DRUG: Placebo
Lead sponsor: Eli Lilly and Company (INDUSTRY)
Collaborators: Boehringer Ingelheim
Enrollment: 215 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2006-12
Completion date: 2008-02
Locations:
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
city: Beijing
country: China
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
city: Changsha
country: China
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
city: Harbin
country: China
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
city: Nanjin
country: China
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
city: Nanjing
country: China
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
city: Shanghai
country: China
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
city: Wuhan
country: China

Summary:
To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.
Molecular and Genetic Analysis of Disturbed Wound Healing in Barbadians With Diabetic Foot Ulcers
Acronym: WHy
ClinicalTrials.gov ID: NCT01002521
Organization: The University of The West Indies
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Impaired Wound Healing
Diabetes Mellitus
Lead sponsor: The University of The West Indies (OTHER)
Collaborators: Chronic Disease Research Centre
Barbados Diabetes Foundation
Enrollment: 605 participants
Eligibility: sex ALL, minimum age , maximum age 
Accepts healthy volunteers: no
Start date: 2009-12
Completion date: 2012-06
Locations:
facility: Chronic Disease Research Centre
city: Bridgetown
state: Saint Michael
country: Barbados

Summary:
This observational study aims to identify risk factors and molecular mechanisms of impaired wound healing, to guide better foot care in the diabetic population.
Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Retinovascular Diseases
ClinicalTrials.gov ID: NCT00001733
Organization: National Institutes of Health Clinical Center (CC)
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Diabetic Retinopathy
Macular Degeneration
Pathologic Neovascularization
Retinal Disease
Lead sponsor: National Eye Institute (NEI) (NIH)
Enrollment: 2000 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: yes
Start date: 1998-03-06
Completion date: 2008-07-02
Locations:
facility: National Institutes of Health Clinical Center, 9000 Rockville Pike
city: Bethesda
state: Maryland
country: United States

Summary:
This screening protocol is designed to help recruit patients for National Eye Institute (NEI) studies of the retina, such as diabetic retinopathy and macular degeneration. Patients must meet the specific criteria of a research study, and this protocol serves as a first step for admitting patients to a retinal disease study.

Candidates will undergo a medical history and comprehensive eye examination. The eye examination includes dilation of the pupils to fully examine the retina. In some studies, photographs of the eye are required. This is done using fluorescein angiography. In this procedure, a dye called sodium fluorescein is injected into the blood stream through a vein. After the dye reaches the blood vessels of the eye, photographs are taken of the retina. Other diagnostic procedures may include physical examination, questionnaires, routine laboratory tests and other standard or specialized tests, as needed.

When the screening is completed, patients will be informed of their options to participate in a study. Patients who are ineligible for a current study will be informed of alternative treatments or options. No treatment is offered under this protocol.
Chrono-restricted Diet and Physical Activity as a New Preventive Strategy for Sarcopenia in Postmenopausal Women With Obesity and Type 2 Diabetes
Acronym: TIMEDIAB
ClinicalTrials.gov ID: NCT07075133
Organization: University Hospital, Toulouse
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Phases: NA
Conditions: Obesity
Sarcopenia
Post Menopause
Type 2 Diabetes
Circadian Clock
Interventions: OTHER: Antidiabetic diet (control)
OTHER: eTRE diet
OTHER: Physical activity in the morning
OTHER: Physical activity in the afternoon
Lead sponsor: University Hospital, Toulouse (OTHER)
Enrollment: 45 participants
Eligibility: sex ALL, minimum age 45 Years, maximum age 70 Years
Accepts healthy volunteers: yes
Start date: 2025-07-15
Completion date: 2029-07-15
Locations:
facility: Rangueil Hospital
city: Toulouse
state: France
country: France

Summary:
The aim of TIMEDIAB is to demonstrate that early TRE (eTRE) combined to late (afternoon) exercise will outperform eTRE combined to morning exercise on muscle function as primary endpoint, and glucose homeostasis as secondary endpoint